布地格福与布地奈德福莫特罗治疗COPD稳定期效果的对照研究

A comparative study of the effect of budigfu and budesonide formoterol in the treatment of chronic obstructive pulmonary disease in the stable stage

目的:比较布地格福与布地奈德福莫特罗治疗慢性阻塞性肺疾病(COPD)稳定期的临床效果。方法:收集2021年3月至2022年3月采用药物治疗的COPD稳定期患者60例,用随机数字表法分为观察组和对照组各30例。观察组给予布地格福吸入气雾剂治疗,2揿/次,2次/d,共10d。对照组给予布地奈德福莫特罗吸入粉雾剂治疗,1吸/次,2次/d,共10 d。比较两组治疗前后血气分析指标、肺功能指标、圣·乔治呼吸问题调查问卷(SGRQ)评分变化情况以及治疗期间药物相关不良反应发生情况。结果:观察组治疗后血酸碱度(pH)、动脉血氧分压(PaO_(2))检测结果均高于对照组,动脉血二氧化碳分压(PaCO_(2))检测结果低于对照组(P<0.05)。观察组治疗后FEV_(1)%、FEV_(1)/FVC检测结果均高于对照组(P<0.05);症状评分、日常活动评分、心理状态评分及SGRQ总评分均低于对照组(P<0.05)。观察组和对照组治疗期间各有2例出现药物相关不良反应(P>0.05)。结论:布地格福与布地奈德福莫特罗治疗COPD稳定期均有显著的疗效和良好的安全性,但布地格福效果更佳,可作为优选药物。

Objective:To compare the clinical effects of budigfu and budesonide formoterol in the treatment of chronic obstructive pulmonary disease(COPD)in the stable phase.Methods:From March 2021 to March 2022,60 patients with COPD in the stable stage were collected,and were divided into an observation group and a control group with 30 cases in each group with random number table method.The observation group was treated with budigfu inhalation aerosol,2 presses/time,2 times/day,for a total of 10 days,and the control group was treated with budesonide formoterol inhalation powder,1 presses/time,2 times/day,for a total of 10 days.The changes of blood gas analysis index,pulmonary function index,St.George’s respiratory questionnaire(SGRQ)score and the occurrence of drug-related adverse reactions were compared between the two groups before and after treatment.Results:After treatment,the detection results of blood pH and arterial partial pressure of oxygen(PaO_(2))in the observation group were higher than those in the control group,and the result of arterial partial pressure of carbon dioxide(PaCO_(2))was lower than that in the control group(P<0.05);the detection results of FEV_(1)%,FEV_(1)/FVC in the observation group were higher than those in the control group after treatment(P<0.05);the symptom score,daily activity score,mental state score and SGRQ total score in the observation group were lower than those in the control group(P<0.05).There were two incidence cases of drug-related adverse reactions in the both observation groups(P>0.05).Conclusion:Budigfu and budesonide formoterol have significant efficacy and good safety in the treatment of COPD in the stable stage,but budigfu is more effective and can be used as the preferred drug.